Uri Abadi

661 total citations
28 papers, 298 citations indexed

About

Uri Abadi is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Uri Abadi has authored 28 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Uri Abadi's work include Lymphoma Diagnosis and Treatment (11 papers), CAR-T cell therapy research (10 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Uri Abadi is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), CAR-T cell therapy research (10 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Uri Abadi collaborates with scholars based in Israel, United States and France. Uri Abadi's co-authors include Gideon Koren, Michael Lishner, Martin Ellis, Itai Levi, Netanel A. Horowitz, Adam J. Olszewski, Naseer Qayum, Abraham Avigdor, Herbert Eradat and Gila Sellam and has published in prestigious journals such as Blood, Hepatology and British Journal of Haematology.

In The Last Decade

Uri Abadi

26 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Uri Abadi Israel	9	141	129	71	49	49	28	298
Geundoo Jang South Korea	12	208 1.5×	117 0.9×	68 1.0×	37 0.8×	27 0.6×	39	396
Muhamad Alhaj Moustafa United States	10	121 0.9×	106 0.8×	88 1.2×	44 0.9×	19 0.4×	89	315
Maria Chiara Tisi Italy	11	142 1.0×	150 1.2×	34 0.5×	65 1.3×	21 0.4×	26	293
Jeremy Ramdial United States	10	129 0.9×	86 0.7×	121 1.7×	63 1.3×	14 0.3×	62	310
Mariana Bastos‐Oreiro Spain	11	180 1.3×	126 1.0×	136 1.9×	73 1.5×	17 0.3×	51	363
Qingsong Yin China	8	156 1.1×	97 0.8×	56 0.8×	97 2.0×	29 0.6×	66	320
Elisa Carraro Italy	12	104 0.7×	125 1.0×	108 1.5×	38 0.8×	14 0.3×	37	392
Elizabeth L. Courville United States	11	147 1.0×	108 0.8×	136 1.9×	64 1.3×	11 0.2×	46	376
Birte Friedrichs Germany	10	134 1.0×	61 0.5×	105 1.5×	147 3.0×	27 0.6×	21	344
Bhausaheb Bagal India	10	146 1.0×	101 0.8×	142 2.0×	92 1.9×	28 0.6×	104	413

Countries citing papers authored by Uri Abadi

Since Specialization

Citations

This map shows the geographic impact of Uri Abadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uri Abadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uri Abadi more than expected).

Fields of papers citing papers by Uri Abadi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uri Abadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uri Abadi. The network helps show where Uri Abadi may publish in the future.

Co-authorship network of co-authors of Uri Abadi

This figure shows the co-authorship network connecting the top 25 collaborators of Uri Abadi. A scholar is included among the top collaborators of Uri Abadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uri Abadi. Uri Abadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gurion, Ronit, Meirav Kedmi, Chava Perry, et al.. (2025). Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting– a retrospective study. Annals of Hematology. 104(7). 3821–3827.

Matasar, Matthew J., Max S. Topp, John N. Allan, et al.. (2024). Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study. Blood. 144(Supplement 1). 866–866. 1 indexed citations

Topp, Max S., Matthew J. Matasar, John N. Allan, et al.. (2024). Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 145(14). 1498–1509. 9 indexed citations

Shochat, Tzippy, Shlomzion Aumann, Boaz Nachmias, et al.. (2023). Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study. Annals of Hematology. 102(8). 2127–2136. 2 indexed citations

Crombie, Jennifer L., Matthew J. Matasar, Max S. Topp, et al.. (2023). Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study. Blood. 142(Supplement 1). 4461–4461. 5 indexed citations

Gurion, Ronit, Meirav Kedmi, Chava Perry, et al.. (2023). Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study. Blood. 142(Supplement 1). 5170–5170. 1 indexed citations

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2022). Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood. 140(Supplement 1). 1778–1780. 27 indexed citations

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2021). MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES. Hematological Oncology. 39(S2). 4 indexed citations

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2021). ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. Clinical Lymphoma Myeloma & Leukemia. 21. S395–S396. 3 indexed citations

10.

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2020). Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 43–45. 43 indexed citations

11.

Pasvolsky, Oren, Adi Zoref‐Lorenz, Uri Abadi, et al.. (2019). Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series. International Journal of Hematology. 109(5). 553–562. 12 indexed citations

12.

Shimony, Shai, Netanel A. Horowitz, Elena Ribakovsky, et al.. (2019). Romidepsin treatment for relapsed or refractory peripheral and cutaneous T‐cell lymphoma: Real‐life data from a national multicenter observational study. Hematological Oncology. 37(5). 569–577. 16 indexed citations

13.

Abadi, Uri, Ronit Gurion, Pnina Rotman‐Pikielny, et al.. (2019). Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma. Leukemia & lymphoma. 60(12). 2922–2926. 6 indexed citations

14.

Dann, Eldad J., Osnat Bairey, Rachel Bar‐Shalom, et al.. (2017). Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. British Journal of Haematology. 178(5). 709–718. 26 indexed citations

15.

Cohen, Keren, Uri Abadi, Aleck Hercbergs, et al.. (2017). The induction of myeloma cell death and DNA damage by tetrac, a thyroid hormone derivative. Endocrine Related Cancer. 25(1). 21–34. 8 indexed citations

16.

Abadi, Uri, et al.. (2014). Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis. 21(5). 397–404. 24 indexed citations

17.

Dann, Eldad J., Osnat Bairey, Rachel Bar‐Shalom, et al.. (2014). Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study. Blood. 124(21). 4409–4409. 3 indexed citations

18.

Abadi, Uri, Gideon Koren, & Michael Lishner. (2011). Leukemia and Lymphoma in Pregnancy. Hematology/Oncology Clinics of North America. 25(2). 277–291. 44 indexed citations

19.

Abadi, Uri, et al.. (2011). Prolonged Blood Storage Does Not Effect Survival in an Animal Model of Hemorrhagic Shock. Transfusion Medicine and Hemotherapy. 38(4). 272–276. 4 indexed citations

20.

Nagler, Arnon, Mark Pines, Uri Abadi, et al.. (2000). Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology. 31(3). 641–648. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact